42 results
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:21pm
or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than … . Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity
424B3
CHRO
Chromocell Therapeutics Corp.
15 May 24
Prospectus supplement
4:15pm
or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions.
Tax positions that meet the more-likely-than … . Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity
10-Q
2024 Q1
CHRO
Chromocell Therapeutics Corp.
15 May 24
Quarterly report
4:06pm
that not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any. Tax positions taken … management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:49pm
on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management … ;
We may be subject to litigation for a variety of claims, which could adversely affect our results of operations, harm our reputation or otherwise
424B3
CHRO
Chromocell Therapeutics Corp.
16 Apr 24
Prospectus supplement
5:45pm
on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management … ;
We may be subject to litigation for a variety of claims, which could adversely affect our results of operations, harm our reputation or otherwise
10-K
EX-19.1
5vw9kqk511
16 Apr 24
Annual report
4:48pm
10-K
2zk 015gk3jvdvk
16 Apr 24
Annual report
4:48pm
8-K
EX-99.1
qneyt8p
9 Apr 24
Chromocell Issues Letter to Stockholders from Chief Executive Officer
8:30am
8-K
EX-99.1
4qahsuzubxm0oxs3
21 Mar 24
Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler
9:00am
8-K
EX-99.1
iqzi16s5 og9d8lmusv
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
nql ivnn4x
13 Mar 24
Regulation FD Disclosure
8:00am
8-K
EX-1.1
jhbi5r9a4ror0m
22 Feb 24
Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering
4:05pm
424B4
2czir132pzqvfi5
20 Feb 24
Prospectus supplement with pricing info
5:30pm
424B4
e8r b8a4w6muci
20 Feb 24
Prospectus supplement with pricing info
5:28pm
FWP
fzn 9jupwf6ybwt6gkq
12 Feb 24
Free writing prospectus
8:09am
FWP
urx9nkkjyu8pm 965sly
6 Feb 24
Free writing prospectus
8:43pm
FWP
5zb2mxy8f
31 Jan 24
Free writing prospectus
4:16pm